Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BAXTER REORGANIZES INTO TWO GROUPS: HOSPITAL/ALTERNATE SITES

Executive Summary

BAXTER REORGANIZES INTO TWO GROUPS: HOSPITAL/ALTERNATE SITES and global businesses. Jim Tobin oversees the international group, which encompasses both the overseas operation and Baxter's medical specialties businesses such as diagnostics, cardiovascular products, blood therapy, etc. Lance Piccolo is heading Baxter's core U.S. businesses under the new arrangement, including products and services for U.S. hospitals, plus Baxter's alternate site activities. The move is the latest stage in a gradual evolution from the 10-group structure implemented immediately after the 1985 merger with American Hospital Supply. In a recent presentation at a symposium sponsored by The Wilkerson Group consulting firm, Baxter Exec VP Robert Simmons said that the change "signals [Baxter's] seriousness" toward maintaining its leadership in U.S. corporate sales. "Baxter now has its entire product and service offering for hospitals organized within a single group," Simmons said. "That arrangement will sharpen even further our efforts in distribution efficiency, system selling, stockless inventory and so forth." Baxter's corporate program accounts for almost 40% of total domestic sales of hospital products, Simmons noted. "We have contracts covering about 30% of all U.S. hospital beds, and our corporate-program revenue accounted for about 50% of Baxter's U.S. sales growth last year," the exec said. Long term, Baxter expects corporate sales to continue to outpace Baxter's overall growth, with corporate sales projected to double by 1992. Purchasing through groups will continue to increase, Simmons predicted. Currently, national consumption of hospital supplies is about $ 29 bil., he said, projected to grow to approximately $ 38 bil. by 1992. Of current spending, "more than three-quarters goes through systems," according to Simmons. American Healthcare Systems and Voluntary Hospitals of America account for 29% of the total, he added. "At the national level as well as the regional and local levels, the key is to get maximum performance from suppliers and maximum compliance from the member hospitals of the group," Simmons concluded.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS014363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel